Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.

What Was Tested

This randomized controlled trial looks at Leuprolide and Flutamide.

This exploratory analysis investigated the effect of race on the clinical outcome of combined androgen blockade (CAB).

Who Took Part

The abstract describes 813 patients taking part.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, men only.

Patients were analyzed according to race (African American [AA], white, or other).

How the Study Was Run

The design is described as randomized, double-blind and multicenter.

The patients were allocated by chance, so the Leuprolide group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Leuprolide, so expectations could not easily colour the readings.

Running at several centres spread the Leuprolide study over different clinics and patient groups.

The primary clinical events were disease progression and survival.

What Was Measured

This exploratory analysis investigated the effect of race on the clinical outcome of combined androgen blockade (CAB).

Topics PubMed links to this paper include Adenocarcinoma, Androgen Antagonists, Anilides, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Black People and Bone Neoplasms.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Leuprolide and Flutamide in 813 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (The Prostate), a journal based in United States.

More context: the related Leuprolide library page, all human trials.